Altfest L J & Co. Inc. Purchases 2,806 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Altfest L J & Co. Inc. increased its stake in Thermo Fisher by 47.7% in Q4, buying 2,806 shares to hold 8,689 shares valued at about $5.035 million.
• Thermo Fisher has a consensus analyst rating of Moderate Buy with a consensus target of $632.50, and several firms raised targets recently (Stifel to $700, Citi to $685).
• The company beat Q4 estimates (EPS $6.57 vs. $6.45; revenue $12.22B vs. $11.95B), reported 7.2% revenue growth year-over-year, and raised its quarterly dividend to $0.47 ($1.88 annual).

Altfest L J & Co. Inc. increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 47.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,689 shares of the medical research company's stock after acquiring an additional 2,806 shares during the period. Altfest L J & Co. Inc.'s holdings in Thermo Fisher Scientific were worth $5,035,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. JPL Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the 3rd quarter valued at $28,000. Highline Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 126.9% in the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock valued at $29,000 after buying an additional 33 shares during the last quarter. Beacon Financial Strategies CORP acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $29,000. Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $29,000. Finally, Capital A Wealth Management LLC increased its stake in Thermo Fisher Scientific by 825.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock valued at $30,000 after buying an additional 66 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on TMO shares. Stifel Nicolaus lifted their price target on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a "buy" rating in a research note on Friday, January 9th. Citigroup lifted their price target on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a "buy" rating in a research note on Friday, January 30th. DZ Bank began coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a "buy" rating and a $610.00 price target on the stock. Wells Fargo & Company set a $683.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Thermo Fisher Scientific in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $632.50.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $496.34 on Friday. The company has a market capitalization of $184.45 billion, a price-to-earnings ratio of 27.98, a PEG ratio of 2.66 and a beta of 0.97. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. The company has a 50-day simple moving average of $505.33 and a 200 day simple moving average of $548.85. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping the consensus estimate of $6.45 by $0.12. The business had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. Thermo Fisher Scientific's revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.10 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's payout ratio is presently 10.60%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the sale, the executive vice president owned 20,752 shares of the company's stock, valued at $11,230,982.40. The trade was a 1.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of the business's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $63,499,170. This represents a 3.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.